Myocardial infarction diagnosis marker-ING1 gene

A myocardial infarction and gene technology, applied in the field of the diagnostic marker of myocardial infarction-ING1 gene, can solve the problem of unclear expression of related genes, and achieve the effect of early diagnosis, reduction of mortality, and better genetic diagnosis.

Inactive Publication Date: 2018-11-13
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF10 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A variety of physiological processes accompany the occurrence of myocardial infarction, such as inflammation, abnormal calcium uptake, cell cycle abnormalities, peptide secretion, oxidative stress, apoptosis, etc., and the precise timing of these processes and the occurrence of myocardial ischemia are currently unknown. When some related genes are expressed is not clear and needs to be further explored

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Myocardial infarction diagnosis marker-ING1 gene
  • Myocardial infarction diagnosis marker-ING1 gene
  • Myocardial infarction diagnosis marker-ING1 gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Screening of genes differentially expressed in patients with myocardial infarction and normal people

[0035] 1. Research object

[0036] Select 6 hospitalized patients with myocardial infarction treated in the hospital as research objects, including 3 males and 3 females, with an average age of 56.00±8.75; 7 healthy people in the control group; each of the above-mentioned patients and healthy people who were invited to participate in the study All signed the informed consent.

[0037] 2. Sample collection and storage

[0038] On the day of admission, 8 mL of fresh sterile arterial blood was collected into EDTA anticoagulated purple tubes before coronary angiography. If it is not used immediately, the sample can be stored in a refrigerator at 4°C for 2 hours.

[0039] 3. Separation of PBMCs by Ficoll method

[0040] The following steps are all completed in the ultra-clean bench:

[0041] (1) Dilute the blood sample with equal volume of normal saline, add ...

Embodiment 2

[0063] Embodiment 2QPCR experiment verifies the genes differentially expressed in patients with myocardial infarction and normal people

[0064] 1. Research object:

[0065] The screening criteria were the same as in Example 1, 35 patients with myocardial infarction and 35 normal subjects.

[0066] 2. Extraction of total RNA in blood

[0067] Step is with embodiment 1.

[0068] 3. RT-PCR

[0069] (1)RT

[0070] RT reaction system (20μl):

[0071]

[0072] RT reaction procedure:

[0073] 42°C 15min

[0074] 85℃ 5s

[0075] 4℃ ---

[0076] (2) qPCR

[0077] PCR reaction system (20μl):

[0078]

[0079] PCR reaction program:

[0080] Amplification procedure:

[0081] Stage 1 95°C 10min

[0082] Stage 2 95°C 10s

[0083] 51°C 10s

[0084] Repeat for 45 cycles

[0085] Three replicate wells were set for each sample, and the internal reference was GAPDH.

[0086] (3) Primers

[0087] The primer sequences of ING1 gene and GAPDH gene are as follows:

[0088] GAP...

Embodiment 3

[0101] Example 3 Western blot experiment to verify the expression products of differentially expressed genes in patients with myocardial infarction and normal people

[0102] 1. Research object: same as embodiment 2.

[0103] 2. Mononuclear cell isolation

[0104] Take 10ml of venous blood from patients with myocardial infarction and normal people, inject it into a sterile vial containing heparin, and shake it gently immediately after capping. Add an equal volume of HBSS (NaCl 8.0g, NaCl 2 HPO 4 0.132g, KH 2 PO 4 0.06g, KCl0.4g, phenol red 1ml, NaHCO 3 0.35g, D-glucose 1.0g, dissolved in 1000ml double distilled water), to reduce the aggregation of red blood cells. Draw 8ml of lymphocyte stratification solution into a 50ml centrifuge tube, slowly add the diluted blood along the tube wall, keep the interface clear, do not mix the two, centrifuge at 20°C 2000r / min for 30min, carefully absorb the stratification solution and plasma transfer The turbid off-white layer, tha...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an ING1 gene which can serve as a diagnosis tool of myocardial infarction. High-throughput sequencing and QPCR (quantitative polymerase chain reaction) research know that the content of the ING1 gene in blood of a myocardial infarction patient remarkably rises as compared with normal people, western blot experiment results show that the content of ING protein in blood of the myocardial infarction patient remarkably rises as compared with normal people, so that the ING1 gene and the ING protein can serve as molecular markers of diagnosis of the myocardial infarction. Thecontent of the gene or the protein in the blood represents the myocardial infarction, so that a representing method has the advantages that tissue sampling detection is avoided, subject pain is relieved, the representing method can be used for screening of healthy people, and the myocardial infarction is effectively prevented.

Description

technical field [0001] The invention belongs to the field of molecular diagnosis and relates to a diagnostic marker of myocardial infarction-ING1 gene. Background technique [0002] Myocardial infarction is a global public health problem that seriously threatens public health (J.Ross, Jr., A50-year research journey. From laboratory to clinic, Circulation journal: official journal of the Japanese Circulation Society, 73(2009) 3-12; D. Lloyd-Jones, R. Adams, M. Carnethon, G. De Simone, T.B. Ferguson, K. Flegal, E. Ford, K. Furie, A. Go, K. Greenlund, N. Haase, S. Hailpern, M. Ho, V. Howard, B. Kissela, S. Kittner, D. Lackland, L. Lisabeth, A. Marelli, M. McDermott, J. Meigs, D. Mozaffarian, G. Nichol, C. O'Donnell, V. Roger, W. Rosamond, R. Sacco, P Sorlie, R. Stafford, J. Steinberger, T. Thom, S. Wasserthiel-Smoller, N. Wong, J. Wylie-Rosett, Y. Hong , C. American Heart Association Statistics, S.). Several methodologies can be effectively applied to the treatment of myocar...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883C12N15/11
CPCC12Q1/6883C12Q2600/158
Inventor 李曙光靳传娣
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap